DxNA to Use its Rapid Detection Platform to Simplify Testing for Swine Flu (H1N1...

DxNA to Use its Rapid Detection Platform to Simplify Testing for Swine Flu
(H1N1 Virus)

Company's 4.5kg "Lab in a Box" Allows for Rapid Onsite Pathogen Detection

ST. GEORGE, Utah, April 29 /PRNewswire/ -- DxNA announced today that in
response to the recent outbreak of swine flu and related world threat, it is
developing a diagnostic test for its GeneSTAT(R) pathogen detection platform
to detect the H1N1 virus (known as swine flu) anywhere it is needed in
approximately 45 minutes using a portable device that weighs less than 10
pounds. The Company anticipates having a product ready for evaluation in 1-2
weeks.

"Such mobile testers can be used by anyone, with the most basic training,"
says John Crowther of the Joint FAO/IAEA Program's Animal Production and
Health section. "The results could immediately be processed back to a central
point, like a mobile phone message. Such tests could revolutionize disease
diagnosis."

DxNA also announced today that it will request the U.S. Food and Drug
Administration (FDA) to grant an Emergency Use Authorization for the H1N1
strain of Swine Flu test using the GeneSTAT platform.

DxNA initially developed its rapid, portable molecular test to detect H5 Avian
Influenza for markets around the world. That test is now being validated by
the Chinese government and other global health organizations. The GeneSTAT
platform includes a device that offers portability and remote usage to rapidly
detect pathogens where outbreaks are suspected. The user-friendly device is
also suitable for use in gateway airports, at local health departments and
schools, where on-site, rapid and non-invasive screening for highly contagious
pathogens is advised. The GeneSTAT test module requires a simple swab of the
mouth, nose or throat. The Company is developing a number of follow-on tests
to detect pathogens that may affect people and agriculture.

"We are in early market release of our first GeneSTAT product, for avian flu,
with validation currently underway by labs in both the United States and
overseas," said Phillip Grimm, Chief Executive Officer of DxNA. "We are now
focused on the swine flu pathogen, and have reached out to health agencies
around the world and offered our assistance in helping to rapidly diagnose
this virus."

Through its rapid, precise, on-site polymerase chain reaction (PCR) genetic
testing capabilities, GeneSTAT technology facilitates the rapid detection of
pathogens and viruses. The World Health Organization has highlighted rapid
detection of pandemics such as swine flu as "crucial" for the rapid
implementation of measures "to stop the pandemic at its source and to prevent
millions of deaths, social disruption, and economic loss."(1) One European
virologist has pointed to the fact that the current lack of rapid field tests
may mean more people have been infected with a pandemic than originally
suspected and pointed to PCR as the most efficient diagnostic method for field
testing.(2)

About GeneSTAT(R)

DxNA's GeneSTAT diagnostic platform technology allows individuals with
approximately five minutes of training to conduct accurate real-time
diagnostic testing almost anywhere. With the GeneSTAT platform, PCR -
previously performed in large clinical laboratories by highly-skilled
personnel - can be performed by almost anyone, in virtually any location,
including airports, laboratories, clinics, or physician's offices.
Furthermore, testing is not limited to developed regions like the United
States, Europe and Japan but also in less-developed rural and economically
challenged regions. Designed with economy in mind, GeneSTAT is inherently less
costly than the PCR devices typical of large clinical laboratories.

About DxNA

DxNA, based in St. George, Utah, and with offices in New York City is a
groundbreaking molecular diagnostics company that develops and distributes
portable, fully-integrated systems and tests for genetic analysis in the
medical, agricultural, and biosecurity markets. The Company's systems and
technologies enable rapid and precise genetic testing to take place on-site by
allowing for otherwise complex, manual, laboratory procedures to be performed
anywhere.

DxNA, together with its distinguished advisory board consisting of Nirbhay
Kumar, Ph.D., Paul Blumenthal, Ph. D., Anthony R. Torres, M.D., and Richard
Webby, Ph.D., is working to commercialize its GeneSTAT diagnostic technology
for rapid PCR detection applications throughout the world. For more
information, please visit www.DxNA.com.

(1)"Global Surveillance During an Influenza Pandemic, Version 1" World Health
Organization Global Influenza Programme, April 2009,
http://www.who.int/csr/disease/swineflu/global_pandemic_influenza_surveilance_apr09.pdf
(Accessed April 29, 2009)

(2)"Testing for Swine Flu No Easy Feat," Reuters, April 29,
2009http://tvnz.co.nz/health-news/testing-swine-flu-no-easy-feat-2685198
(Accessed April 29, 2009)

SOURCE DxNA

Dan Budwick, BMC Communications Group, LLC, +1-973-271-6085,
dbudwick@bmccommunications.com; or Craig Mosman, DxNA, LLC, +1-435-628-0324
ext. 104, Craig.M@dxna.com